Suppr超能文献

Myc在血液系统恶性肿瘤中响应HDAC抑制诱导miRNA介导的细胞凋亡。

Myc Induces miRNA-Mediated Apoptosis in Response to HDAC Inhibition in Hematologic Malignancies.

作者信息

Adams Clare M, Hiebert Scott W, Eischen Christine M

机构信息

Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.

Department of Biochemistry, Vanderbilt University Medical Center, Nashville, Tennessee.

出版信息

Cancer Res. 2016 Feb 1;76(3):736-48. doi: 10.1158/0008-5472.CAN-15-1751. Epub 2015 Dec 16.

Abstract

Alterations in the expression or function of histone deacetylases (HDAC) contribute to the development and progression of hematologic malignancies. Consequently, the development and implementation of HDAC inhibitors has proven to be therapeutically beneficial, particularly for hematologic malignancies. However, the molecular mechanisms by which HDAC inhibition (HDACi) induces tumor cell death remain unresolved. Here, we investigated the effects of HDACi in Myc-driven B-cell lymphoma and five other hematopoietic malignancies. We determined that Myc-mediated transcriptional repression of the miR-15 and let-7 families in malignant cells was relieved upon HDACi, and Myc was required for their upregulation. The miR-15 and let-7 families then targeted and downregulated the antiapoptotic genes Bcl-2 and Bcl-xL, respectively, to induce HDACi-mediated apoptosis. Notably, Myc also transcriptionally upregulated these miRNA in untransformed cells, indicating that this Myc-induced miRNA-mediated apoptotic pathway is suppressed in malignant cells, but becomes reactivated upon HDACi. Taken together, our results reveal a previously unknown mechanism by which Myc induces apoptosis independent of the p53 pathway and as a response to HDACi in malignant hematopoietic cells.

摘要

组蛋白去乙酰化酶(HDAC)表达或功能的改变有助于血液系统恶性肿瘤的发生和发展。因此,HDAC抑制剂的开发和应用已被证明具有治疗益处,特别是对血液系统恶性肿瘤。然而,HDAC抑制(HDACi)诱导肿瘤细胞死亡的分子机制仍未明确。在此,我们研究了HDACi对Myc驱动的B细胞淋巴瘤和其他五种血液系统恶性肿瘤的影响。我们确定,HDACi作用后,恶性细胞中Myc介导的miR-15和let-7家族的转录抑制被解除,且Myc是它们上调所必需的。然后,miR-15和let-7家族分别靶向并下调抗凋亡基因Bcl-2和Bcl-xL,以诱导HDACi介导的凋亡。值得注意的是,Myc在未转化细胞中也转录上调这些miRNA,这表明这种Myc诱导的miRNA介导的凋亡途径在恶性细胞中受到抑制,但在HDACi作用后会重新激活。综上所述,我们的结果揭示了一种此前未知的机制,即Myc在恶性造血细胞中独立于p53途径并作为对HDACi的反应诱导凋亡。

相似文献

1
Myc Induces miRNA-Mediated Apoptosis in Response to HDAC Inhibition in Hematologic Malignancies.
Cancer Res. 2016 Feb 1;76(3):736-48. doi: 10.1158/0008-5472.CAN-15-1751. Epub 2015 Dec 16.
2
Histone deacetylase inhibition reveals a tumor-suppressive function of MYC-regulated miRNA in breast and lung carcinoma.
Cell Death Differ. 2016 Aug;23(8):1312-21. doi: 10.1038/cdd.2016.9. Epub 2016 Feb 26.
7
Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas.
Oncogene. 2012 Jun 14;31(24):3002-3008. doi: 10.1038/onc.2011.470. Epub 2011 Oct 17.
8
ATF3 Repression of BCL-X Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types.
Clin Cancer Res. 2017 Sep 15;23(18):5573-5584. doi: 10.1158/1078-0432.CCR-17-0466. Epub 2017 Jun 13.

引用本文的文献

2
Chidamide and venetoclax synergistically regulate the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL.
Ann Hematol. 2025 Jan;104(1):489-501. doi: 10.1007/s00277-024-06110-2. Epub 2024 Nov 28.
3
NOXA Accentuates Apoptosis Induction by a Novel Histone Deacetylase Inhibitor.
Cancers (Basel). 2023 Jul 17;15(14):3650. doi: 10.3390/cancers15143650.
4
An integrative systems biology approach to overcome venetoclax resistance in acute myeloid leukemia.
PLoS Comput Biol. 2022 Sep 13;18(9):e1010439. doi: 10.1371/journal.pcbi.1010439. eCollection 2022 Sep.
7
MTBP and MYC: A Dynamic Duo in Proliferation, Cancer, and Aging.
Biology (Basel). 2022 Jun 8;11(6):881. doi: 10.3390/biology11060881.
8
Function of BCLAF1 in human disease.
Oncol Lett. 2022 Feb;23(2):58. doi: 10.3892/ol.2021.13176. Epub 2021 Dec 22.
9
Propranolol Suppresses Proliferation and Migration of HUVECs through Regulation of the miR-206/VEGFA Axis.
Biomed Res Int. 2021 Oct 16;2021:7629176. doi: 10.1155/2021/7629176. eCollection 2021.
10
Targeting Myc Interacting Proteins as a Winding Path in Cancer Therapy.
Front Pharmacol. 2021 Sep 29;12:748852. doi: 10.3389/fphar.2021.748852. eCollection 2021.

本文引用的文献

1
MicroRNA-31 is a transcriptional target of histone deacetylase inhibitors and a regulator of cellular senescence.
J Biol Chem. 2015 Apr 17;290(16):10555-67. doi: 10.1074/jbc.M114.624361. Epub 2015 Mar 3.
2
Miz-1 regulates translation of Trp53 via ribosomal protein L22 in cells undergoing V(D)J recombination.
Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5411-9. doi: 10.1073/pnas.1412107111. Epub 2014 Dec 2.
4
Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles.
Nature. 2014 Jul 24;511(7510):483-7. doi: 10.1038/nature13473. Epub 2014 Jul 9.
5
Inactivation of p53 is insufficient to allow B cells and B-cell lymphomas to survive without Dicer.
Cancer Res. 2014 Jul 15;74(14):3923-34. doi: 10.1158/0008-5472.CAN-13-1866. Epub 2014 May 19.
6
Oncogenic protein MTBP interacts with MYC to promote tumorigenesis.
Cancer Res. 2014 Jul 1;74(13):3591-602. doi: 10.1158/0008-5472.CAN-13-2149. Epub 2014 May 1.
7
Class I HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy.
Antioxid Redox Signal. 2015 Jul 1;23(1):51-65. doi: 10.1089/ars.2014.5915. Epub 2014 Jun 26.
8
New and emerging HDAC inhibitors for cancer treatment.
J Clin Invest. 2014 Jan;124(1):30-9. doi: 10.1172/JCI69738. Epub 2014 Jan 2.
9
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy.
Nat Rev Mol Cell Biol. 2014 Jan;15(1):49-63. doi: 10.1038/nrm3722.
10
miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma.
J Invest Dermatol. 2014 Apr;134(4):1101-1107. doi: 10.1038/jid.2013.461. Epub 2013 Nov 7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验